JADPRO | Volume 4, Supplement 1 (Nov/Dec 2013)

Nursing Perspectives on Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Guest Editor
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C

The supplement and associated publication costs were funded by Onyx Pharmaceuticals, Inc. Fishawack Communications, Inc., provided medical writing and editorial assistance, supported by Onyx Pharmaceuticals.

Review Article

Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a malignant plasma cell disorder with potential secondary organ effects including renal, bone, and bone marrow effects as well as neurologic and immune dysfunction. Diagnostic evaluation of MM includes laboratory...

Prescriber's Corner

Carfilzomib

Review Article

The Side Effect Profile of Carfilzomib: From Clinical Trials to Clinical Practice

Treatment of patients with relapsed and/or refractory multiple myeloma (RR MM) is challenging due to the heterogeneity of the disease, patient comorbidities, and side effects of individual treatments. Carfilzomib, a selective proteasome ...

Grand Rounds

Treatment of Patients With Multiple Myeloma: A Relapsed and Refractory Case Study

Review Article

Treatment With Carfilzomib: A Promising Future for Multiple Myeloma

The survival outlook for patients with multiple myeloma (MM) has improved over the past decade; however, even with access to newer therapies, all patients will eventually relapse and progress. Carfilzomib is a selective proteasome inhibi...